Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03846050 · ClinicalTrials.gov registry record · NA
Alcohol Impaired Driving: From the Laboratory to the Natural Environment
A NA study of Drinking and Driving, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- NA
- Development phase
- 230
- Enrollment target
- 1
- Study location
NCT03846050: Completed NA study of Drinking and Driving, sponsored by University of Missouri-Columbia.
NCT03846050 is a NA study of Drinking and Driving that has completed, run by University of Missouri-Columbia. The registered enrollment target is 230 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03846050, a NA study of Drinking and Driving, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- NA
- Development phase
- 230 participants
- Enrollment target
- 1
- Study location
Study Summary
This project combined laboratory and ambulatory assessment (AA) methods to test decision making associated with alcohol impaired driving (AID). Participants will complete a laboratory alcohol administration session followed by 6 weeks of mobile assessment. Data from drinking events will be examined to test how individuals make choices about driving or not after consuming alcohol.
Primary Outcome
Participants will provide self-reported driving behavior (yes/no driven a vehicle) after drinking alcohol during the AA portion. This assessment will be taken from their daily smartphone responses.
Conditions Studied
Interventions
- BEHAVIORAL BAC feedback/warning
- BEHAVIORAL No BAC feedback/warning
Study Locations (1)
Missouri
- University of Missouri-Columbia - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2018-12-15 |
| Est. Completion | 2024-06-01 |
| Phase | NA |
What the finished NCT03846050 record still lists
NCT03846050 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Drinking and Driving appearing as the primary indexed condition, and to 2 interventions - of which BAC feedback/warning is the first listed.
NCT03846050 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03846050 about?
NCT03846050 is a clinical study titled "Alcohol Impaired Driving: From the Laboratory to the Natural Environment". This project combined laboratory and ambulatory assessment (AA) methods to test decision making associated with alcohol impaired driving (AID). Participants will complete a laboratory alcohol administration session followed by 6 weeks of mobile assessment. Data from drinking events will be examined ...
What is the current status of trial NCT03846050?
This trial is currently completed. It is a NA study. The enrollment target is 230 participants. The study started on 2018-12-15. Estimated completion is 2024-06-01.
What conditions does trial NCT03846050 study?
This clinical trial studies the following conditions: Drinking and Driving.
What interventions are being tested in trial NCT03846050?
The interventions under investigation include: BAC feedback/warning (BEHAVIORAL), No BAC feedback/warning (BEHAVIORAL).
Who is sponsoring clinical trial NCT03846050?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03846050 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03846050's enrollment target sits among peer trials
230 465th of 2000 higher than 1,533 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI